MedTrace Logo

Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer

NCT01298362 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 290

Last updated 2016-09-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to identify the combined impact on bone loss as well as the incidence of bone fractures in women with estrogen receptor (ER)-positive, early breast cancer treated with an aromatase inhibitor (AI) either as first line therapy or as maintenance therapy after initial treatment with chemotherapy, in real life clinical settings in Greece.

Conditions

Interventions

DRUG

Aromatase Inhibitors

DRUG

Chemotherapy

Sponsors & Collaborators

  • Hellenic Breast Surgeons Society

    lead OTHER

Principal Investigators

  • Christos J Markopoulos, MD, MPhil · Associate Professor of Surgery-Athens University Medical School, Director of the Breast Unit-Athens Medical Centre Private Hospital

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-12-31
Completion
2014-03-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01298362 on ClinicalTrials.gov